Table 1.
ROR and PRR of psychiatric AEs among 19 drugs.
| Drug category | Drug target | Number of psychiatric AEs (a) | Total number of AEs (a+b) | Percentage of psychiatric AEs [a/(a+b)] | ROR (95% CI) | P_value_ROR | PRR (95% CI) | χ2 | P_value_PRR |
|---|---|---|---|---|---|---|---|---|---|
| Antidiabetic drugs | ABCC8+KCNJ11∗ | 522 | 6940 | 7.52% | 1.51 (1.38, 1.65) | 1.56E-19 | 1.47 (1.39, 1.56) | 83.8 | 3.81E-39 |
| Antidiabetic drugs | DPP4 | 647 | 26,378 | 2.45% | 0.47 (0.43, 0.51) | 2.11E-67 | 0.48 (0.4, 0.56) | 383.3 | 1.22E-17 |
| Antidiabetic drugs | GLP1R | 1218 | 50,432 | 2.42% | 0.46 (0.43, 0.49) | 4.02E-120 | 0.47 (0.42, 0.53) | 754.7 | 4.40E-37 |
| Antidiabetic drugs | PPARG | 197 | 53,836 | 0.37% | 0.07 (0.06, 0.08) | 1.68E-287 | 0.07 (0, 0.21) | 2502.0 | 1 |
| Antidiabetic drugs | SLC5A2 | 1057 | 67,339 | 1.57% | 0.3 (0.28, 0.31) | 0 | 0.31 (0.25, 0.37) | 1742.5 | 1.13E-31 |
| Antihypertensive agents | ACE | 3457 | 87,128 | 3.97% | 0.77 (0.74, 0.79) | 2.42E-55 | 0.78 (0.74, 0.81) | 233.2 | 4.47E-27 |
| Antihypertensive agents | ADRB1∗ | 7455 | 105,052 | 7.10% | 1.42 (1.39, 1.46) | 3.11E-172 | 1.39 (1.37, 1.42) | 865.9 | 5.54E-284 |
| Antihypertensive agents | AGTR1 | 2578 | 79,569 | 3.24% | 0.62 (0.6, 0.65) | 3.28E-121 | 0.63 (0.6, 0.67) | 573.1 | 1.54E-60 |
| Antihypertensive agents | CCB∗ | 9489 | 100,768 | 9.42% | 1.94 (1.9, 1.98) | 0 | 1.85 (1.83, 1.87) | 3889.9 | 0 |
| Antihypertensive agents | SLC12A3 | 796 | 18,701 | 4.26% | 0.83 (0.77, 0.89) | 4.58E-07 | 0.83 (0.77, 0.9) | 27.8 | 2.84E-06 |
| Lipid-lowering drugs | HMGCR | 5766 | 137,391 | 4.20% | 0.81 (0.79, 0.84) | 2.69E-41 | 0.82 (0.8, 0.85) | 235.0 | 1.09E-37 |
| Lipid-lowering drugs | NPC1L1 | 271 | 8643 | 3.14% | 0.6 (0.53, 0.68) | 9.36E-16 | 0.61 (0.5, 0.73) | 69.2 | 3.05E-07 |
| Anti-stroke agents | F10 | 2062 | 170,257 | 1.21% | 0.23 (0.22, 0.24) | 0 | 0.24 (0.19, 0.28) | 5373.3 | 3.50E-47 |
| Anti-stroke agents | F2 | 473 | 48,321 | 0.98% | 0.18 (0.17, 0.2) | 0 | 0.19 (0.1, 0.28) | 1701.8 | 2.57E-10 |
| Anti-stroke agents | P2RY12 | 1687 | 106,795 | 1.58% | 0.3 (0.28, 0.31) | 0 | 0.31 (0.26, 0.36) | 2753.5 | 3.39E-45 |
| COPD medications | ALOX5 | 6 | 145 | 4.14% | 0.8 (0.35, 1.82) | 5.96E-01 | 0.81 (0.03, 1.59) | 0.3 | 8.35E-01 |
| COPD medications | CYSLTR1∗∗ | 6007 | 21,230 | 28.29% | 7.37 (7.16, 7.6) | 0 | 5.57 (5.55, 5.59) | 23600.1 | 0 |
| COPD medications | PDE4∗ | 599 | 6018 | 9.95% | 2.06 (1.89, 2.24) | 2.00E-62 | 1.95 (1.87, 2.03) | 292.3 | 3.96E-223 |
| NSAIDs | PTGS1+PTGS2∗ | 16,523 | 305,619 | 5.41% | 1.06 (1.05, 1.08) | 5.14E-16 | 1.06 (1.05, 1.08) | 58.7 | 5.14E-16 |
Disproportionality analysis were performed by calculating the ROR and PRR. Significant adverse reaction signals (the number of reports was not less than three and the lower limit of the 95% CI of the ROR exceeds one) were marked with an asterisk (∗). Robust signals (meeting additional criteria of a PRR of at least 2 and a chi-squared value of at least 4) were marked with two asterisks (∗∗).